Elranatamab is in clinical development for relapsed/refractory multiple myeloma (MM). MM is a rare, incurable cancer of the blood that develops from plasma cells in the bone marrow (the spongy tissue inside the inner part of some bones) where large amounts of abnormal plasma cells are produced and interfere with the production of red and white blood cells and platelets. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (relapsed MM). Eventually the periods without symptoms will shorten and the illness will become resistant to treatment (refractory MM). Most patients will experience serial relapse to existing treatments at some point during their disease course (relapsed MM), hence the need for newer treatment options.
Elranatamab is a novel type of cancer immunotherapy that brings an antigen (a substance that induces an immune response in the body) found on the cancer cells closer to a person’s own T-cells (a type of white blood cell that is part of the immune system) to kill the cancer cells. Elranatamab is administered by subcutaneous injection, which is intended to allow higher doses than intravenous administration without increasing adverse events. If licensed, elranatamab will offer a new treatment option for patients with relapsed/refractory MM.
Pralsetinib is in clinical development for the treatment of thyroid cancer. Thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck that produces hormones. Thyroid cancer can happen when there are genetic changes in the thyroid cells, which cause them to grow uncontrollably …